Tanvex BioPharma Inc. (Taiwan Stock Code: Tanvex-KY) announced on October 8 that its consolidated revenue for September reached NT$84.86 million, marking a month-on-month increase of approximately 260% and a staggering 3,916% year-on-year growth. This represents the company’s highest monthly revenue on record and drove third-quarter consolidated revenue to exceed NT$100 million for the first time, reaching NT$125 million.

Calculated in the company’s functional currency, the U.S. dollar, Tanvex BioPharma’s consolidated revenue for Q3 totaled US$4.08 million—an increase of over 160% compared with the previous quarter. This also marks the second consecutive quarter of growth since its merger with Bora Pharmaceuticals, signaling that integration synergies are taking effect and that Tanvex BioPharma has officially entered a phase of accelerated operational expansion.

According to Tanvex BioPharma, the revenue surge was primarily driven by shipments of its biosimilar product TX-01, which was launched in the U.S. market in September through its commercial partner Cipla. In addition, market share gains achieved by its Canadian partner Sandoz further boosted overall performance. Total shipment revenue from TX-01 biosimilar products reached nearly US$1.5 million in September alone—surpassing the entire shipment revenue achieved in 2024 to date. Meanwhile, the company’s CDMO (Contract Development and Manufacturing Organization) business revenue also grew nearly 50% quarter-on-quarter as client projects continued to advance.

With TX-01’s official U.S. market launch, Tanvex BioPharma has become the first Taiwanese biopharmaceutical company to achieve commercial-scale production and successful product launch experience in the United States, marking a key milestone in the global CDMO competitive landscape.

Furthermore, Tanvex BioPharma’s San Diego manufacturing facility is currently undergoing expansion to increase production capacity by 2,000 liters according to schedule. Upon completion, the facility will be capable of supporting more late-stage clinical and commercial manufacturing projects. This capacity upgrade not only strengthens Tanvex BioPharma’s core competitiveness in the global CDMO market but also lays a solid foundation to meet the growing demand from its U.S.-based clients—positioning the company for sustained long-term growth.

Resource: 泰福9月營收8,486萬元、年增39倍 第3季首度突破億元關卡